Incyte (INCY) Tops Q3 EPS by 46c
Get Alerts INCY Hot Sheet
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues: 3.21M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Incyte (NASDAQ: INCY) reported Q3 EPS of $1.18, $0.46 better than the analyst estimate of $0.72. Revenue for the quarter came in at $813 million versus the consensus estimate of $738.52 million.
2021 Financial Guidance:
The Company has reaffirmed its full year 2021 financial guidance, as detailed below. Guidance does not include revenue from Opzelura in the U.S., Minjuvi in Europe or the impact of any potential future strategic transactions.
|
|
| |
| Current | Previous | |
Jakafi net product revenues | $2,125 - $2,170 million | Unchanged | |
Other Hematology/Oncology net product revenues | $155 - $170 million | Unchanged | |
GAAP Cost of product revenues | 6 – 7% of net product revenues | Unchanged | |
Non-GAAP Cost of product revenues1 | 5 – 6% of net product revenues | Unchanged | |
GAAP Research and development expenses | $1,350 - $1,390 million | Unchanged | |
Non-GAAP Research and development expenses2 | $1,220 - $1,250 million | Unchanged | |
GAAP Selling, general and administrative expenses | $725 - $755 million | Unchanged | |
Non-GAAP Selling, general and administrative expenses3 | $655 - $680 million | Unchanged |
1 Adjusted to exclude the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated cost of stock-based compensation.
2 Adjusted to exclude the estimated cost of stock-based compensation.
3 Adjusted to exclude the estimated cost of stock-based compensation and legal settlements.
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Dime Community Bancshares (DCOM) Tops Q1 EPS by 1c
- Incyte (INCY) Announces Acquisition of Escient Pharmaceuticals
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!